Investors can profit from some of these, but there are different markets that are stronger. Let’s look at three of them and see how they can be great investing options.

1. Fintech

The fintech market has digital-payment platforms and online banking services, along with cryptocurrency platforms. This market keeps expanding as people switch from cash to shop online more, and depend less and less on traditional banks.

Businesses are also beginning to see the value of streamlining their payments, integrating tools into mobile apps, and taking advantage of analytics to track their customers’ purchases. Allied Market Research predicts the mobile payment market to expand globally at a compound annual growth (CAGR) of 30.1% between last year and 2027 to reach $12.06 trillion.

Companies that might profit from this explosion are PayPal (PYPL), which has its popular online-payment platform that reaches 377 million accounts, and Square (SQ), which handles payments for merchants and allows consumers to make peer-to-peer payments through its app.

2. AI

The AI market is usually thought of as being only “smart robots” but its scope is actually much larger. AI services are now being used to calculate data for advertising platforms, processing large amounts of info to aid companies in making choices.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

They can also power chatbots to help a company’s customer-support, or help optimize a company’s supply chain by finding inefficiencies, and increasing safety standards by finding hazards.

The global AI industry increased to $39.9 billion in 2019, as reported by Grand View Research, but might go even further with a CAGR of 42.2% through now and 2027.

My top stocks in this sector include NVIDIA (NVDA), which gives high-end GPUs for completing AI tasks, and Palantir (PLTR), which finds and processes data for federal agencies and corporate customers.

3. VR and AR

The virtual reality and augmented reality sectors are still small but they have both expanded and have great growth potential.

VR devices, which put users inside digital environments, can be used by more than just video games, simulations and even socialization. Facebook‘s Oculus system has a first-mover’s advantage in this sector, and its headsets might expand Facebook’s ecosystem beyond mobile devices.

AR devices, which push digital images onto real-world environments, can be used like heads-up displays for particular professions.

One company worth keeping an eye on in this market is Vuzix (VUZI), which mostly sells AR smartglasses to corporate customers. It is a small company but they have an early-mover’s advantage in the AR market, and might keep expanding as more people and companies get into AR glasses.

The global AR and VR markets might expand at a CAGR of 42.9% between 2020 and 2030, according to reports by Research and Markets, and become a $1.27 trillion sector. That is a bullish prediction suggesting that VR and AR devices might become the next big platforms after smartphones.

Don’t be so fast to embrace that saying. While there is data to support the theory that stocks don’t do well after May and October, some terrible years can change the average return during this time, to look downward. During a normal, bullish market, the next months could be as progressive as any other. And if you have the right stocks, it could be even more profitable.

So here are three of those types of stocks. Ones with great growth opportunities and are ripe for buying this month.

1. Entegris

For the first time in seven quarters, last month, Entegris’ (ENTG) earnings fell lower than analysts’ consensus estimates. Its Q1 top line was short from expectations too, though it grew by 24% y/y. The company’s Q2 predictions for earnings per share was between $0.77 and $0.82 on revenue of around $530 or $545 million is pretty much what analysts modeled, and well higher from last year’s numbers of $0.60 per share and sales at $448.4 million. But investors could not get over the earnings miss, maybe wondering if the company is being harmed by the chip shortage that is working against other companies.

It is a worry, however, that ignores the true dynamic of the low supply of semiconductors.

The shortage is connected to incredible global demand. This means Entegris is doing the same business it was doing before covid harmed supply lines. The firm is actually getting greater demand as users of its components try to offset the shortage by optimizing their yields and improving their current technologies; that is where an advanced process solutions provider like this one can change everything.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

Despite last quarter’s not so great results, analysts say the company is on track to grow its revenue by almost 17% this year, with profits increasing by almost 25%.

2. Align Technology

Align Technology (ALGN) might not be a well-known name yet, but there is a good probability someone you know is using its product. It’s among the top companies making invisible braces. You may know it as Invisalign.

The coronavirus forced large problems onto the company as dentists contributed to the virus-reduction effort by only performing emergency procedures. Align Technology’s Invisalign requires a trip to a dentist to get your teeth scanned; it does not offer scanning through a “SmileShop” or through an at-home dental kit as competitors do.

Customers do seem to like having their dentists do this kind of work, however. With the COVID pandemic pulling back and dental practices getting back toward normal work, Align’s Q1 revenue was not just higher by 62%, but hit a record-breaking $895 million. Analysts say this growth level will continue for the rest of 2021, and while sales growth should eventually decrease in pace, the market is still seeking double-digit percentage growth through 2022. Profit growth could be even better.

The stock price is down by 7% from last week’s high, but that sell-off seems to be more like profit-taking than a reason to worry.

3. The Trade Desk

Finally, lets talk about The Trade Desk (TTD) and why you should add it to your list of stocks to invest in before May ends.

The Trade Desk gives the advertising industry a cloud-based solution that optimizes ad-buying. More than just buying traditional advertising, it uses consumer data and campaign management tools to guarantee that advertisers get the most bang for their buck.

Not only has covid not been an issue for the company, it has even accelerated The Trade Desk’s success. Last year, its revenue increased by 26%, almost doubling per-share profits. Analysts anticipate sales growth of 35% for 2021, with a rebounding economy helping out. While these analysts are also predicting an earnings lull in 2021, understand that this company has not failed to beat earnings estimates since 2017. The current outlook seems to underestimate what could happen.

However, the stock is having relatively bad performance since it reached a high in December. While most of the 28% price pullback since then can be said to be about profit-taking, it’s not like The Trade Desk is not doing great.

GameStop (GME) and biopharma Bausch Health Companies (BHC) are two firms that have put themselves back on the path for growth — after experiencing a downturn for a long time. Shares of these two stocks are higher by 2,790% and 82%, over the past year. 

These companies also have attracted substantial institutional demand. Ryan Cohen, the co-founder of Chewy, is personally steering GameStop’s momentum after buying a 13% stake in the firm. Meanwhile, billionaire hedge fund guru Carl Icahn bought 7.83% of Bausch Health’s shares. Here’s how these businesses might push forward.

1. GameStop

It was obvious from the start what this retailer needed to make a comeback: close their unprofitable locations, invest in e-commerce, and change its outdated services. 

The problem was no one believed in its future. Lenders believed the company was going extinct and stayed far away. Due to short-selling, its share price also stayed low to cause equity financing to be impossible. 

That changed when the legendary short squeeze, which happened on Reddit, sent its stock skyrocketing. Thanks to this boost, GameStop brought in $551 million in cash by selling only 3.5 million units (around 4% of the firm). A year ago, it would have brought in just $13.2 million by selling this same total.

With this cash, it was able to deal with its long-term debt. Now, GameStop is primed for growth. Last year, the company’s e-commerce went up by a stunning 191%. Online sales of consoles, video games, and collectibles are now 30% of its revenues of $5.09 billion.

The best thing about GameStop is its current low valuation. Despite its new momentum and cash balance, the stock is only at 2.26 times revenue. Stocks in the retail sector usually go for between 0.8 times to 4.5 times revenue, with more e-Commerce sales meaning a higher value. So there is certainly room for more money to be made.

2. Bausch Health Companies 

Bausch Health Companies is a pharma company with a dark history. Formerly called Valeant Pharmaceuticals, the company started a streak of leveraged purchases in the early 2010s. It had vast piles of debt, bought a competitor, laid off staff and raised its prices, and continued on to the next while its profit margins increased. This stopped suddenly in 2015 after an accounting scandal and political anger over its price-increasing dealt a heavy blow.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

Now, Bausch Health is a group of contact lens makers and eye care company Bausch + Lomb, various dermatology companies and Salix Pharmaceuticals. The company has $24.1 billion in debt and generates only $1.428 billion per year in earnings.

Over $15 billion of its $8 billion in annual revenue goes to interest alone. The firm only has $452 million for the R&D to produce new drugs every year. 

The fact that it is still alive is a miracle. But, despite poor choices, the former CEO of Valeant Pharmaceuticals, Michael Pearson, made one smart move: the buying of Bausch + Lomb in 2013 for $8.7 billion. Due to the growth of contact lenses, Bloomberg says the subsidiary’s value could be between $20 billion and $30 billion.

Right now, Bausch is trying to unload its Bausch + Lomb company. If it finds someone to buy the subsidiary for anywhere close to that price, it might remove its debt and start new. It is also thinking of doing a spinoff of Bausch + Lomb away from its core business to silo out its liabilities.

Trading at just 1.45 times sales, Bausch might be a buy if it can come back from debt and chart a path forward. For now, the firm makes enough money to pay its interest and refinance when debt principles are due. It is now a bargain compared to the average pharma stock which are usually priced at five times revenue.